WO2004098489A3 - Compositions and methods for modulation of specific epitopes of hsp60 - Google Patents

Compositions and methods for modulation of specific epitopes of hsp60 Download PDF

Info

Publication number
WO2004098489A3
WO2004098489A3 PCT/IL2004/000404 IL2004000404W WO2004098489A3 WO 2004098489 A3 WO2004098489 A3 WO 2004098489A3 IL 2004000404 W IL2004000404 W IL 2004000404W WO 2004098489 A3 WO2004098489 A3 WO 2004098489A3
Authority
WO
WIPO (PCT)
Prior art keywords
hsp60
residues
binding
compositions
modulation
Prior art date
Application number
PCT/IL2004/000404
Other languages
French (fr)
Other versions
WO2004098489A2 (en
Inventor
Hubert Kolb
Original Assignee
Peptor Ltd
Hubert Kolb
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peptor Ltd, Hubert Kolb filed Critical Peptor Ltd
Publication of WO2004098489A2 publication Critical patent/WO2004098489A2/en
Publication of WO2004098489A3 publication Critical patent/WO2004098489A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Distinct epitopes of HSP60 are identified to modulate binding and activation of macrophages. One epitope, localized to residues 335-366, and more specifically to residues 254-265, of human HSP60 binds LPS and by presenting it to toll receptor-4 complex immunostimulates the cells, and a second epitope, localized to residues 481-500 of HSP60, is responsible for binding to the macrophage cell surface. The present invention relates to novel compounds, capable of inhibiting the binding of those peptidic regions to LPS or to macrophages. The present invention further relates to pharmaceutical compositions comprising these novel compounds, useful for prevention or treatment of inflammatory and autoimmune diseases and disorders.
PCT/IL2004/000404 2003-05-12 2004-05-12 Compositions and methods for modulation of specific epitopes of hsp60 WO2004098489A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46938903P 2003-05-12 2003-05-12
US60/469,389 2003-05-12

Publications (2)

Publication Number Publication Date
WO2004098489A2 WO2004098489A2 (en) 2004-11-18
WO2004098489A3 true WO2004098489A3 (en) 2006-09-14

Family

ID=33435227

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2004/000404 WO2004098489A2 (en) 2003-05-12 2004-05-12 Compositions and methods for modulation of specific epitopes of hsp60

Country Status (1)

Country Link
WO (1) WO2004098489A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, hsp60 peptides and t cell vaccines for immunomodulation
CN113493788B (en) * 2021-05-24 2023-06-23 上海晶诺生物科技有限公司 Mycobacterium promoter library and application thereof
US20230321185A1 (en) * 2021-11-18 2023-10-12 Azam Moosavi Method for treatment of type-1 diabetes in a subject in need thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997002016A1 (en) * 1995-07-05 1997-01-23 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of t cell mediated diseases
WO1997001959A1 (en) * 1995-06-30 1997-01-23 Yeda Research And Development Co. Ltd. Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997001959A1 (en) * 1995-06-30 1997-01-23 Yeda Research And Development Co. Ltd. Novel peptides derived from human heat shock protein 60 for treatment of diabetes, compositions, methods and kits
WO1997002016A1 (en) * 1995-07-05 1997-01-23 Yeda Research And Development Co. Ltd. Preparations and methods for the treatment of t cell mediated diseases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GENESEQ [online] 23 January 1988 (1988-01-23), ZASLOFF M.A., Database accession no. (AAP82735) *
DATABASE GENESEQ [online] 23 January 1997 (1997-01-23), COHEN ET AL., Database accession no. (AAW12353) *
DATABASE GENESEQ [online] 23 January 1997 (1997-01-23), COHEN ET AL., Database accession no. (AAW33045) *
DATABASE GENESEQ [online] 8 September 1987 (1987-09-08), ZASLOFF M.A., Database accession no. (AAP71207) *

Also Published As

Publication number Publication date
WO2004098489A2 (en) 2004-11-18

Similar Documents

Publication Publication Date Title
WO2007098420A3 (en) Peptides that block the binding of igg to fcrn
WO2006113909A3 (en) Humanized anti-cd70 binding agents and uses thereof
AU2003274342A1 (en) Compositions for the treatment of autoimmune disorders
EP2154157A3 (en) FC region variants
EP2360169A3 (en) PSMA antibodies
WO2004024068A3 (en) Novel composition and methods for the treatment of immune related diseases
WO2007002701A3 (en) Anti-inflammatory aryl nitrile compounds
MX338122B (en) Therapeutic epitopes and uses thereof.
IL201889A (en) Therapeutic compositions for the treatment of immune related disorders comprising antibodies that specifically recognize the nk 1.1 antigen or the cd56 antigen expressed by nk t cells
WO2006004910A3 (en) Improved bispecific antibodies
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
WO2004074455A3 (en) Fc REGION VARIANTS
WO2001036487A3 (en) Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
WO2003057006A3 (en) Use of antibodies against the muc18 antigen
WO2005048935A3 (en) Methods of modulating immunity
WO2004039247A3 (en) Compositions and methods for pain reduction
WO2006127152A3 (en) Methods for making and using regulatory t cells
AU2003291719A1 (en) Cholesterol absorptions inhibitors for the treatment of autoimmune disorders
WO2007002811A3 (en) Methods and compositions for treating melanoma
WO2005097826A3 (en) Prokineticin 2beta peptide and its use
AU2003298911A1 (en) Cyclosporins for the treatment of autoimmune diseases
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2004098489A3 (en) Compositions and methods for modulation of specific epitopes of hsp60
WO2004024072A3 (en) Novel compositions and methods for the treatment of immune related diseases
WO2004081199A3 (en) Novel compositions and methods for the treatment of immune related disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase